LumosVar — a name inspired by Harry Potter — could help physicians provide genomic-based treatments for their patients
By conjuring the spell “Lumos!” wizards in the mythical world of Harry Potter could light up the tip of their magic wands and illuminate their surroundings. So, too, does LumosVar, a computer program developed by the Translational Genomics Research Institute (TGen), “light up” cancer-causing genetic Var-ients, or mutations, illuminating how physicians might best treat their patients.
A study published today in the scientific journal Frontiers in Oncology describes how researchers at TGen, an affiliate of City of Hope, developed LumosVar to create a tool that can accurately identify cancer-causing mutations from patient tumor samples.
In the case of archived samples from patients for which treatment outcome results are known, these represent a treasure trove of information that could accelerate research by investigators and physicians in predicting responses of future patients to particular treatments.
“There are many open questions in precision oncology that can only be answered by collecting large amounts of patient genomic data linked to treatment response and clinical outcomes,” said Dr. Rebecca Halperin, a Research Assistant Professor in TGen’s Quantitative Medicine and Systems Biology Program.
“The approach we outline in this study should enable researchers to use archival samples more effectively. Accurately calling, or identifying, somatic variants — those DNA changes specific to a patient’s cancer — are the first step in any analysis,” said Dr. Halperin, the study’s lead author.
However, archived tumor samples are frequently not accompanied by the patients’ normal — or germline — genetic information, making it difficult to distinguish the patient’s normal DNA variants to their mutated and cancerous DNA changes.
LumosVar is a precise enough tool that it not only can detect the cancerous DNA from a patient sample, but it also can differentiate the adjacent normal DNA that may surround the tumor in the sample. Comparing the patient’s normal DNA from a suspected cancer-causing mutation is critical to eliminating benign, non-cancerous variants in the sample — “false positives” — and ensuring that the tissue sample analysis is as accurate as possible.
A high level of accuracy is needed for physicians to use this information in precision medicine, determining what treatment each individual patient should receive.
“The sequencing of DNA from tissue adjacent to the tumor could help identify somatic, or cancer-causing, mutations when another source of normal tissue is not available,” said Dr. Sara Byron, Research Assistant Professor in TGen’s Integrated Cancer Genomics Division, and also the study’s senior author.
Learn more: AS IF BY MAGIC: TGEN DEVELOPS PROGRAM THAT LIGHTS UP CANCER-CAUSING MUTATIONS
The Latest on: Genomic-based treatments
[google_news title=”” keyword=”genomic-based treatments” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Genomic-based treatments
- Fujitsu introduces "explainable AI" for use in genomic medicine and cancer treatment planningon May 8, 2024 at 5:00 pm
These tests confirmed that Fujitsu’s technology can accurately support the identification of two main types of lung cancer, for example, by illuminating the factors behind the pathological ...
- Microbiome studies help explore treatments for genetic disorderson May 7, 2024 at 6:31 am
A collaboration has led to the identification, in a bacterium of the intestine, of new CRISPR-Cas9 molecules that could have a clinical potential to treat genetic diseases such as retinitis pigmentosa ...
- Exploring the Microbiome Reveals Novel Treatments for Genetic Disorderson May 7, 2024 at 1:43 am
A new CRISPR-Cas9 molecule produced by a bacterium in the gut microbiome could have clinical potential to treat genetic diseases.
- Alzheimer’s genetic discovery raises hopes of early treatmenton May 6, 2024 at 10:10 am
Almost everyone over the age of 65 who carry two copies of the APOE4 gene variant will develop the disease, scientists said ...
- First sickle cell patients begin gene therapy treatments by bluebird bio, Vertexon May 6, 2024 at 8:47 am
Five months after bluebird bio Inc. won FDA approval for its gene therapy to treat sickle cell disease, the Somerville company said its first patient has begun treatment.
- Advancing genomic medicine: National Cancer Center Japan's role in personalized cancer treatmenton May 2, 2024 at 5:00 pm
In a significant stride towards personalized cancer care, the National Cancer Center Japan (NCCJ) has marked a decade of progress in cancer genomic medicine (CGM).
- Cancer patients gain important benefits from genome-matched treatmentson May 2, 2024 at 3:43 pm
A new study provides compelling evidence that genome-matched treatments can provide significant patient benefit.
- 9 Things Black Breasties Should Know About Genetic Testingon April 29, 2024 at 3:14 pm
Considering genetic testing? Here are 10 things you should know about genetic testing and the impact it can have on your health.
- 10 Things You Should Know About Genetic Testingon April 29, 2024 at 12:00 pm
Considering genetic testing? Here are 10 things you should know about genetic testing and the impact it can have on your health.
- Examining the impact of gene-based breeding on agriculture and medicineon April 25, 2024 at 10:22 am
A research team has demonstrated that gene-based breeding (GBB) offers a transformative approach to advancing plant and animal breeding, showing remarkable predictability, speed, and ...
via Bing News